ArticleAnnals of vascular surgery2025
GLP-1 Receptor Agonists Associated With Improved Survival After Infrainguinal Bypass in Diabetic Patients.
Article in Annals of vascular surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe American Diabetes Association recommends the use of glucagon-like-peptide-1 receptor agonists (GLP1-RAs) (e.g., Ozempic) for patients with atherosclerotic cardiovascular disease, including peripheral artery disease. We hypothesized increasing the use of GLP1-RAs would be associated with improved outcomes after bypass.
methodsRetrospective review of diabetic patients undergoing infrainguinal bypass at a multihospital institution between 2017 and 2024 was conducted, including patient characteristics, operative details, and outcomes. The primary outcome was survival. Secondary outcomes included perioperative complications, major adverse limb events, major adverse cardiovascular events (MACE), and metabolic changes. Kaplan-Meier and Cox regression evaluated outcomes.
resultsA total of 322 patients (62.5% male, 78.8% White, median age 68 [61-76] years) underwent 339 bypasses. GLP1-RA use increased from 8.2% to 18.8% during the study period (P = 0.001). Patients on a GLP1-RA (n = 38, 11.2%) were younger (65.5 [57.0-71.0] vs. 69.9 [62.0-77.0] years, P = 0.003) and had a higher body mass index (29.6 [26.9-33.3] vs. 27.2 [23.3-31.1] kg/m
conclusionGLP1-RA use is increasingly common in patients undergoing lower extremity bypass and was associated with significantly improved postoperative survival and freedom from MACE. Further studies are required to confirm reasons for differences in outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.